Diabetes mellitus (DM) can be cured by adequate insulin secretion from a relatively small volume of cells. Cell encapsulation enables allo-and even xeno-geneic cell therapy without immunosuppression. Micro-encapsulated islets used in recent clinical trials are not fully retrievable after transplantation. This paper summerizes the development of retrievable and theoretically replaceable macro-encapsulated islets using polyvinyl alcohol (PVA) hydrogel. An aqueous solution of PVA becomes a gel through micro crystallization by freezing and thawing. Utilizing this feature, PVA-macro-encapsulated islets (PVA-MEIs) were developed. Rat islets suspended in Euro-Collins solution containing 3% PVA were encapsulated in a mesh-reinforced PVA hydrogel sheet by freezing and thawing. The feasibility of PVA-MEIs for DM therapy was tested in vitro and in vivo. PVA-MEIs showed glucose-responsive insulin secretion in vitro even after 14-day culture. Rat PVA-MEIs cultured in media containing fresh human plasma showed no morphological changes and maintained insulin content. Intra-peritoneal transplantation of PVA-MEIs containing 750 rat islets ameliorated hyperglycemia in streptozotocin (STZ)-induced diabetic mice to nearly normal levels for up to 30 days with a consistent increase in body weight. Transplantation of PVA-MEIs also prevented metabolic and renal disorders in STZ-induced diabetic mice. PVA-MEIs cryo-preserved for 1, 7, and 30 days showed similar function in vitro and corrected hyperglycemia after intra-peritoneal transplantation in STZ-induced diabetic mice. Intra-peritoneal transplantation of PVA-MEIs containing iso-or allo-geneic islets (approx. 2,000 islets) ameliorated hyperglycemia in STZ-induced diabetic rats in a similar manner for almost half a year although the efficacy gradually decreased with time. Transplantation of PVA-MEIs ameliorated hyperglycemia in diabetic mice and rats without immunosupression. Retrievable and theoretically replaceable PVA-MEIs that can secure cell entrapment can mitigate the potential risks associated with xeno-geneic cells and cells made from undifferentiated cells. Therefore, PVA-MEIs are a promising modality for future DM therapy.
Introduction
Diabetes mellitus (DM) is a leading cause of morbidity and mortality in industrialized countries, with the number of DM patients estimated to be 366 million in 2011 and anticipated to increase to 552 million by 2030 [1] . Serious complications such as chronic renal failure, retinopathy, and neuropathy frequently progress in severe-DM patients, in whom β-cell function is virtually lost. Therefore, it is urgent to develop DM therapies. β-cell reconstruction is currently achieved only by either pancreas or islet transplantation in a clinical setting. However, these therapies share the problems of donor scarcity and adverse effects related to immunesuppression. To solve these problems, clinical trials of micro-encapsulated islets that enable transplantation without immunosuppression are being conducted [2] . However, microcapsules, whose diameter is less than a few millimeters, are not retrievable or replaceable once they are transplanted. Recognizing this weakness, the authors have developed macroencapsulated islets (MEIs) that can be seen by the naked eye and manually handled, allowing them to be surgically retrievable and theoretically replaceable. Here, our previous studies on polyvinyl alcohol (PVA)-MEIs are summerized.
Preparation of PVA-MEIs
PVA-MEIs were prepared as described in our previous reports [3] [4] [5] [6] . Briefly, to prepare PVA solution, 3 g of PVA (polymerization degree = 8,800) was dissolved in 75 ml of double-distilled (d-d) water, supplemented with 10 ml of concentrated (X 10) Euro-Collins (EC) solution containing 10 mM nicotinamide (Sigma, St. Louis, MO), and then supplemented with 10 ml of fetal bovine serum (FBS) (JRH BIOSCIENCES, A CSL Company, USA. Lot no. 8N2277) and 5 ml of dimethyl sulfoxide (DMSO) (Sigma, USA). The original EC solution has the following composition: d-glucose, 35 g/l; K 2 HPO 4 , 7.4 g/l; KH 2 PO 4 , 2.05 g/l; KCl, 1.12 g/l; NaHCO 3 , 0.84 g/l.
Rat (Wistar unless otherwise mentioned) islets were isolated using the collagenase (type XI, Sigma) digestion method and separated by dextran gradient [7, 8] . Isolated islets were hand-picked and cultured in CMRL-1066 medium (Sigma) supplemented with 10% FBS, 10 mm nicotinamide, and an antibiotic-antimycotic solution (GibcoBRL Life Technologies Inc., Grand Island, NY).
After being cultured for 24 h in CMRL-1066 medium, isolated rat islets were washed, counted, and pooled in a 1.5 ml centrifuge tube, and then suspended in 1 ml of Cell Banker (BLC-1, Code, 630-01601, Wako Pure Chemical Industries, Ltd. Japan) for 5 min. After centrifugation, the islets were resuspended in 100 µl of PVA solution to a total volume of approximately 200 µl, then plated on a flat polyethylene terephthalate (PET) mesh (TNo. 60SS, Nippon Tokushu Fabric Inc., Japan) (20 mm × 15 mm), which was immersed in the same PVA solution and spread on a glass plate before use. Another piece of mesh was placed over the mixture. These meshes were used to reinforce the hydrogel. Then, another glass slide was placed over the device to control the thickness to 1 mm. The device was kept in a refrigerator at -80 °C for 24 h, which resulted in gel formation after crystallization. The sheet-type macro-encapsulation device was then carefully removed from between the glass slides, thawed rapidly in a 37 °C CMRL-1066 medium bath for a few seconds, and then immersed in 5 ml of cold (4 °C) University of Wisconsin (UW) solution (Bristol-Myers Squibb Company, USA) for 5 min for islet thawing. After three washes with UW solution, the device was immersed in 5 ml of cold UW solution for 24 h at 4 °C. The device was then washed two times with CMRL-1066 medium supplemented with 10% FBS and cultured in this medium at 37 °C in 5% CO 2 /95% air to start the assessments (Fig. 1) . A polyethylene terephthalate mesh was used to improve physical strength (modified from [3] ).
In vitro validation studies
PVA-MEIs or free islets were cultured in CMRL-1066 medium for 14 days. After 1-day culture, the recovery rate of islets was determined and the insulin content was measured using acid-ethanol (75% vol/vol ethanol, 23.5% d-d water, and 1.5% 10 N HCl) extraction and enzyme-linked immunosorbent assay (ELISA) (Shibayagi Co. Ltd., Gunma, Japan) with rat insulin as the standard.
After 1-, 7-, and 14-day culture, an insulin secretion test was performed. After 1 h of preincubation in 2 ml of CMRL-1066 culture medium containing 3.3 mM glucose and 0.1% bovine serum albumin (NACALAI TESQUE, Inc. Kyoto, Japan) in a 37 °C water bath with shaking, PVA-MEIs and free islets were incubated in CMRL-1066 medium containing 3.3 mM glucose for 1 h. They were then washed with CMRL-1066 medium containing 3.3 mM glucose, and then further incubated in CMRL-1066 medium containing 16.7 mM glucose for 1 h. Finally, the devices and free islets were washed and incubated again in CMRL-1066 medium containing 3.3 mM glucose for 1 h. At the end of each incubation period, the media were collected and frozen at -20 °C for the insulin assay.
After 1-day culture, the recovery rate of islets and the insulin content were not different between PVA-MEIs and free islets ( Fig. 2(a) ). Glucose-dependent insulin secretion was observed in both groups after 1-day culture. It was maintained for 14 days in PVA-MEIs but no longer observed after 7-day culture in free islets ( Fig. 2(b) ).
In order to examine immuno-isolation effect, PVA-MEIs or free islets were cultured in CMRL medium containing 10% or 20% fresh human plasma (FHP) of AB blood type or 10% FBS. Changes in morphology and number of islets were observed with time. After 48 h of culture, the insulin content was measured as described above.
Free rat islets were destroyed with time by 10% or 20% FHP, whereas rat PVA-MEIs maintained their normal shape ( Fig. 3(a) ). The number of islets did not change in PVA-MEIs, but significantly decreased in the FHP groups of free islets ( Fig. 3(b) ). Insulin content after 48 h of culture, in comparison to that in the FBS groups, did not decrease in PVA-MEIs, even in the FHP groups. However, that of free islets significantly decreased in the FHP groups in comparison to free islets in FBS, resulting in significant differences between free islets and MEIs in 10% and 20% FHP groups ( Fig. 3(c) ).
In vivo transplantation
Male C57BL/6 mice (Shimizu Laboratory Supplies Co. Ltd., Kyoto, Japan), aged 8-10 weeks were made diabetic by a single injection of streptozotocin (STZ; Sigma, 220 mg/kg body weight, freshly dissolved in citrate buffer, pH 4.5) into the peritoneal cavity 7-12 days before transplantation. Only mice with non-fasting blood glucose (NFBG) levels of more than 450 mg/dl were used as recipients. PVA-MEIs containing 750 rat islets or an empty PVA sheet with an area of 20 mm × 15 mm and a thickness of 1 mm was intra-peritoneally transplanted. Blood glucose levels were measured with time for 1 month.
Hyperglycemia of the DM mice was significantly (p < 0.001) reduced to almost normal levels by the transplantation of PVA-MEIs (Fig. 4) . As shown later (Figs. 5 and 7), normal blood glucose levels in mice in a fed state is around 150 mg/dl. An increase in body weight was also observed in the transplantation group (data not shown).
In order to examine effects on diabetic renal damage, PVA-MEIs containing 800 rat islets or an empty PVA sheet were intra-peritoneally transplanted into STZ-induced diabetic mice. DM mice transplanted with an empty PVA sheet (sham) and normal mice without STZ injection served as control groups. Blood glucose levels and body weight were measured with time and blood urea nitrogen (BUN) and creatinine levels were measured weekly for up to 8 weeks. The kidneys of the mice were pathologically examined by periodic acid-Schiff (PAS) staining. The extent of mesangial matrix overgrowth was determined with an image analyzer (Mac ASPECT version 2.3.2, Mitani Co., Tokyo, Japan) and was expressed as mesangial area/glomerular area (%). Blood glucose levels decreased and body weight showed a slight increase after PVA-MEI transplantation (Figs. 5(a) and 5(b)), whereas severe metabolic disorder continued in the sham-operated mice, all of which died within 8 weeks (Fig. 5(c) ). BUN and creatinine levels decreased to almost normal levels after PVA-MEI transplantation, but remained elevated in the sham-operated mice (Figs. 5(d) and 5(e) ). Pathological examination of the kidneys showed a significant increase in mesangial area in the sham-operated mice, but no significant increased in the PVA-MEI transplanted mice (Fig. 5(f) ).
Free
In order to compare iso-and allo-transplantation in rats, PVA-MEIs measuring 30 mm × 25 mm × 1 mm were made for rat experiments. Each device contained islets isolated from three Lewis or Wistar donor rats (mean ± standard error of the mean: 1940 ± 39 islets) and was intra-peritoneally transplanted into an STZ-induced (55 mg/kg) diabetic recipients of Lewis strain. Blood glucose levels and body weight were measured with time for 24 weeks. Diabetic Lewis rats transplanted with either a corresponding amount of free Lewis islets or Wistar islets to the renal subcapsular space served as positive and negative controls, respectively. Normal Lewis rats served as a normal control.
Diabetic Lewis rats transplanted with Lewis islets (L-L) showed significant and consistent reduction in non-fasting blood glucose. In contrast, DM Lewis rats transplanted with Wistar islets (W-W) showed only transient lowering of blood glucose for a week, which then increased to levels that caused continuous hyperglycemia. DM Lewis rats transplanted with PVA-MEIs of Wistar origin (PVA (W-L)) showed a significant reduction in blood glucose, but never reached normal levels. Similarly, DM Lewis rats transplanted with PVA-MEIs of Lewis origin (PVA (L-L) showed a significant but incomplete reduction in blood glucose. The blood glucose levels of these groups gradually increased starting from 6 weeks after transplantation. Statistical analyses showed that the blood glucose level of PVA (W-L) was lower than that of the W-L group and higher than that of the L-L group. However, those of PVA (W-L) and PVA (L-L) were not significantly different ( Fig. 6(a) ). Changes in body weight showed almost normal weight gain in the L-L group and no, or very slight, gain in the W-L group. Slow but continuous weight gain was observed in both PVA (W-L) and PVA (L-L) groups (Fig. 6(b) ).
Cryoperservation
PVA-MEIs containing rat islets were made with freezing durations of 7 and 30 days in addition to normal 1-day freezing. An in vitro insulin secretion test was performed in these 3 groups. In addition, PVA-MEIs containing 800 rat islets were intra peritoneally transplanted to STZ-induced diabetic mice. Normal mice and DM mice without any treatment served as controls. Blood glucose levels and body weight were examined with time. At the end of the experiment, serum insulin and Cpeptide levels were measured and devices were histologically examined.
In the in vitro insulin secretion test, all three groups showed glucose-dependent insulin secretion, with slightly lower insulin secretion in the 30-day preservation group (Fig. 7(a) ). In the in vivo transplantation experiment, all three groups showed significant reduction in blood glucose (Fig. 7(b) ) and maintained body weight for 4 weeks (Fig. 7(c) ) in comparison to those of DM mice without treatment. The blood glucose levels in the 30-day preservation group were slightly higher than those for the 1-and 7-day preservation groups. At the end of the experiment, serum insulin ( Fig. 7(d) ) and Cpeptide ( Fig. 7(e) ) levels in the 1-, 7-, and 30-day preservation groups were significantly higher than those of the DM control group. In the histological examination, no islets were found in the pancreas in the STZ-treated groups regardless of PVA-MEI transplantation. Islets with similar morphology were found in the device regardless of preservation duration (data not shown). 
Histological examination of retrieved devices
Devices of PVA-MEIs were retrieved from the recipient animals at the end of experiments and histologically examined. The samples were fixed in 4% paraformaldehyde solution for 24 h, followed by immersion in 70% ethanol at 4 °C for 24-48 h. Next, the samples were embedded in paraffin. 5-to 6-µm-thick sections were made and stained with hemotoxylin/eosin (H&E) and/or for insulin.
All the macro-encapsulation devices could be retrieved intact after 30 days, 8 weeks, and 24 weeks of transplantation from the abdominal cavity. Histological examination of the retrieved grafts revealed viable islets within the device (Figs. 8(a), 8(b) , and 8(d)), with some islets not viable (Fig. 8(c) ). A thin cellular layer seemed to adhere to the surface of the device 30 days after transplantation (Fig. 8(a) ). The surface of the device was covered by a thin fibrous layer 8 weeks after transplantation (Figs. 8(b) and 8(c) ). The fibrous layer seemed to become thicker 24 weeks after transplantation ( Fig. 8(d) ). These results suggest that PVA, although having good bio-compatibility, induces a foreign-body response, with a fibrous layer growing slowly but steadily. Cellular infiltration into the capsule was not seen in any of the implants, suggesting protection by PVA gel against cellular immunity. Device retrieved from allo-geneic rat abdominal cavity 24 weeks after transplantation (insulin staining, original magnification X100) (modified from [3] , [4] , and [6] ).
Discussion
The goal of a bio-artificial pancreas (BAP) is to enable islet transplantation without immunosuppression by protecting islets from immune rejection with a semipermeable barrier. BAPs can be used not only for allotransplantation but also for xenotransplantation of the islets depending on the immunoisolation property of the barrier. There are several types of BAP, including diffusion chamber, blood perfusion, and encapsulation types [9] .
The encapsulation type of BAPs can be divided into two categories, namely micro-encapsulation and macroencapsulation. In micro-encapsulation, one or a few islets are encapsulated in a hydrogel, such as alginate, creating structures similar to microbeads. This type is favorable for substance exchange because of its large surface area, but is difficult to retrieve once implanted into the body, for example, in the abdominal cavity. In contrast to micro-encapsulation, macroencapsulation encloses islets in a larger device or hydrogel that can be handled macroscopically. Therefore, macro-encapsulated islets are easy to retrieve if adverse events, such as infection, occur and easy to replace if the function decays with time, although the efficacy of replacement has yet to be confirmed experimentally. In addition, secure cell-entrupment and retrievability make the device suitable for early use of artificially generated β-like cells because they can be retrieved in case of any kind of adverse events such as tumor formation [9] .
The effect of a microporous membrane surrounding transplanted cells on immune rejection has been long investigated [10, 11] . Several kinds of diffusion chamber with semipermeable membranes have been studied for the xenotransplantation of islets [11, 12] . Commercially available diffusion chambers, such as TheraCyte [13] , have been used in various studies, including those on islet transplantation [14, 15] and cell differentiation toward islet cells [16] . However, TheraCyte is unsuitable for clinical diabetes therapy because of its limited volumetric capacity (largest capacity: 40 µl). Our research group also studied a diffusion-chamber-type BAP with PVA hydrogel [17] . Our BAP was initially tube-shaped [17] and then was changed into a mesh-reinforced bag [18] . This bag evolved into the PVA-MEIs reported here.
Micro-encapsulation was first reported in the 1980s [19] . Various materials have been tested for this purpose, such as cross-linked alginate [19] , alginate-polylysine-alginate membranes [20] , and agarose gel [21] , to improve biocompatibility, physical strength, and function of islets. Some researchers have applied micro-encapsulation materials to macro-encapsulation. In our research group, agarose-based hydrogel initially used for micro-encapsulation [22] was successfully applied to macro-encapsulation [23] . Dufrane et al. made macro-encapsulated porcine islets using alginate and reported its efficacy in subcutaneous implantation in nonhuman primates [24] . A major problem with this kind of macro-encapsulation is how to increase physical strength, since the materials used for micro-encapsulation become notably fragile as the size of the device increases. In this regard, PVA hydrogel is highly elastic and physically strong. Our PVAMEIs were further reinforced with two PET meshes. This paper summarized our previous studies on PVAMEIs [3] [4] [5] [6] . These studies showed that PVA-MEIs enabled rat-to-mouse xenotransplantation of islets without immunosuppression causing amelioration of hyperglycemia, metabolic disorder, and diabetic renal damage [3, 4] . In in vitro studies, PVA-MEIs maintained islet function longer than did free islets in culture [3] and were protected from xeno-geneic attack by humoral factors [6] . In the rat experiment, transplantation of PVA-MEIs of iso-and allo-geneic origin showed a similar effect for up to 24 weeks, suggesting that, although the function of PVA-MEIs is impaired by encapsulation compared to that of iso-geneic free islet transplantation, PVA-MEIs can maintain their function without the influence of the allo-geneic immune response [6] . In addition, cryopreservation experiments showed that PVA-MEIs can be cryopreserved for up to 30 days without complete loss of their function. This feature of PVA-MEIs enables easy transportation and islet accumulation and, further, it allows enough time for confirmation of safety and efficacy before use, which is unique to PVA-MEIs.
As to the mechanism of immuno-isolation by PVA gel, encapsulated islets were protected from xeno-geneic hyperacute rejection by FHP (Fig. 3) , indicating that complement, a major factor in hyperacute rejection, is blocked by the gel. Histological examination (Fig. 8) showed complete absence of inflammatory cell infiltration in the gel, indicating that cellular immunity is blocked by the gel. In addition, a previous study on the permeability of PVA hydrogel showed a very low permeability coefficient of immunoglobulin G (IgG) in comparison to those of glucose and insulin [25] , and our study suggests that IgG is practically impermeable in PVA gel (data not shown).
Conclusion
This paper summarized our studies on PVA-MEIs, which are useful for xenotransplantation because of their immunoisolation function. PVA-MEIs can thus potentially be used for the early application of artificially processed β-like cells because of their easy retrieval. They are suitable for large distribution due to their cryopreservability. Further studies on PVA-MEIs are necessary to allow their clinical application.
